Compare OFLX & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFLX | SENS |
|---|---|---|
| Founded | 1975 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Industrial Machinery/Components |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.1M | 301.2M |
| IPO Year | 2005 | 2014 |
| Metric | OFLX | SENS |
|---|---|---|
| Price | $31.15 | $6.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.38 |
| AVG Volume (30 Days) | 46.2K | ★ 540.0K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $98,296,000.00 | $16,389,000.00 |
| Revenue This Year | N/A | $74.15 |
| Revenue Next Year | N/A | $58.60 |
| P/E Ratio | $147.24 | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $25.58 | $0.41 |
| 52 Week High | $37.92 | $8.75 |
| Indicator | OFLX | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 45.61 |
| Support Level | $28.96 | $4.79 |
| Resistance Level | $31.82 | $5.94 |
| Average True Range (ATR) | 0.88 | 0.22 |
| MACD | 0.14 | 0.08 |
| Stochastic Oscillator | 93.85 | 55.38 |
Omega Flex Inc is a manufacturer of flexible metal hoses, which is used in a variety of ways to carry gases and liquids within their particular applications. Omega sells its products under the TracPipe, CounterStrike, DoubleTrac, DEF-Trac and MediTrac brands. It serves various markets which include construction, manufacturing, transportation, petrochemical, pharmaceutical, and other industries. Geographically Omega Flex, Inc operates in the United States. The company derives revenues from the manufacture and sale of flexible metal hose and accessories.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.